ORAJEL MOUTH GEL
Active substance(s): BENZOCAINE / BENZOCAINE / BENZOCAINE
NAME OF THE MEDICINAL PRODUCT
Orajel Mouth Gel
QUALITATIVE AND QUANTITATIVE COMPOSITION
Benzocaine 10% w/w
For full list of excipients, see Section 6.1.
For temporary relief from the pain and tenderness associated with mouth ulcers and
from wearing dentures.
Posology and method of administration
Adults and children over 12 years.
Clean and dry the affected area.
Cut off tip of tube on score mark.
Apply a thin layer of Orajel Mouth Gel to the areas inside the mouth which
are tender or painful.
Use up to 4 times daily, for no longer than 4 days.
If tenderness or pain persists, consult your dentist or doctor.
Not for use in children below the age of 12 years.
Known sensitivity to benzocaine or any of the other ingredients.
Not to be used in those individuals suspected of lacking the normal ability to convert
methaemoglobin to haemoglobin, see Section 4.4 Special warnings and precautions
for use and Section 4.8 Undesirable effects.
Not for use in children below the age of 12 years.
Special warnings and precautions for use
Orajel Mouth Gel is intended for short-term use until a dentist or doctor can be
consulted. Treatment with benzocaine products such as Orajel Mouth Gel may mask
symptoms associated with more serious conditions and may therefore delay
Do not use continuously. Do not exceed recommended dose. The product contains
sorbic acid and propylene glycol, which may cause local skin reactions, e.g. contact
Avoid drinking hot liquids whilst using Orajel Mouth Gel.
Do not use if there is a family history of methaemoglobinaemia.
Interaction with other medicinal products and other forms of interaction
Benzocaine, like other derivatives of para-aminobenzoic acid, inhibits the actions of
sulphonamides and therefore should not be used concomitantly with any
Pregnancy and lactation
There is inadequate evidence of safety of benzocaine in human pregnancy, but it has
been in wide use for many years without apparent ill consequences. No clinical data
are available on the use of this product during pregnancy or lactation.
Effects on ability to drive and use machines
No effect on subjects' ability to drive or operate machines.
Application of benzocaine on skin and mucous membranes has resulted in
hypersensitivity reactions (burning, stinging, pruritis, erythema, rash and oedema),
contact dermatitis and methaemoglobinaemia in a few cases in infants, children and
If symptoms persist, or are severe, or are accompanied by fever, headache,
breathlessness, nausea and vomiting, consult a doctor.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse reactions
the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Excessive absorption of benzocaine may produce methaemoglobinaemia in infants,
children, and adults. The first clinical signs are cyanotic (greyish) skin discolouration
(most notably on mucous membranes) and signs of unusual breathing or
Methaemoglobinaemia may be treated by the intravenous administration of 1 %
methylene blue. Treatment of overdose should be symptomatic and supportive.
Pharmacotherapeutic group: Local anaesthetics, ATC code: N01BA05
Benzocaine is a local anaesthetic of the ester type, acting to produce reversible loss of
sensation by preventing or diminishing the generation and transmission of sensory
nerve impulses near the site of application. Depolarisation of the neuronal membrane
and ion exchange are reversibly inhibited.
Benzocaine is rapidly absorbed through mucous membranes and damaged skin.
Anaesthetics of the ester type are hydrolysed by esterases in the plasma and, to a
lesser extent, in the liver.
Preclinical safety data
There are no additional pre-clinical data of relevance to the prescriber.
List of excipients
FD&C Red No. 40 (Allura Red AC): E129
Passion Fruit Flavour
Polyethylene Glycol 3350
Propylene Glycol: E1520
Sodium Saccharin: E954
Sorbic Acid: E200
Special precautions for storage
No special precautions for storage.
Nature and contents of container
Low density polyethylene tube with external acrylate coating, medium density
polypropylene cap. Tubes contain 5.3 g gel.
Special precautions for disposal
MARKETING AUTHORISATION HOLDER
Church & Dwight UK Limited
Premier House, Shearway Business Park
MARKETING AUTHORISATION NUMBER(S)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
21 September 2000
DATE OF REVISION OF THE TEXT
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.